<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2BD4D4F3-7D93-41A3-844F-83DFC280D7BC"><gtr:id>2BD4D4F3-7D93-41A3-844F-83DFC280D7BC</gtr:id><gtr:name>Mgb Biopharma Limited</gtr:name><gtr:address><gtr:line1>151 WEST GEORGE STREET</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G2 2JJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2BD4D4F3-7D93-41A3-844F-83DFC280D7BC" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>2BD4D4F3-7D93-41A3-844F-83DFC280D7BC</gtr:id><gtr:name>Mgb Biopharma Limited</gtr:name><gtr:address><gtr:line1>151 WEST GEORGE STREET</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G2 2JJ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>100000.0</gtr:offerGrant><gtr:projectCost>220336.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5720F96C-21E0-41BB-B37D-273F7F4A1913"><gtr:id>5720F96C-21E0-41BB-B37D-273F7F4A1913</gtr:id><gtr:firstName>Raymond</gtr:firstName><gtr:surname>Spencer</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710161"><gtr:id>0FEDA102-3516-4EEB-B784-189A7D97E51B</gtr:id><gtr:title>Parenteral Formulation for New Class (DNA Minor Groove Binder) Anti-Infective</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710161</gtr:grantReference><gtr:abstractText>MGB's preclinical candidate drug MGB BP3 is a potent anti-infective compound with high
potency against Gram +ve bacteria, including life threatening highly resistant strains such as
MRSA. The compound shows unusual physicochemical characteristics which make
solubilisation very challenging As a result, MGB Biopharma has been forced to adopt an oral
formulation to treat just a subset of bacterial infections - that of Clostridium difficile. The
formulation for that indication was recently successfully shown to be superior to the gold
standard drug (vancomycin) in the classic Hamster model. To be able to utilise this new class
of drug against the most troublesome infectious diseases we need to extend the formulations
in development to be able to successfully produce a reproducible and stable product capable
of being given by the intravenous route to patients who are at risk of death due to resistant
bacterial and other infections.</gtr:abstractText><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>100000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710161</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>